A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

Francesco Ciccia, Angelo Ferrante, Giovanni Triolo, Rosalia Impastato, Alfonso Principato, Maria Concetta Miceli, Giovanni Triolo, Francesco Ciccia, Anna Rita Giardina, Angelo Ferrante, Rosalia Impastato

Risultato della ricerca: Articlepeer review

33 Citazioni (Scopus)

Abstract

The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and disease modifying antirheumatic drugs in quite a number of patients. Tumor necrosis factor inhibitors have demonstrated to be of value in reducing AS disease activity in clinical trials. The efficacy and safety of both etanercept and infliximab in patients with ankylosing spondylitis were compared in a 2-year open label randomised study. Our results are consistent with a significant more rapid clinical improvement in the infliximab treated group. Treatment with both etanercept and infliximab at the end of the study was effective, safe, and well tolerated. © 2009 Springer-Verlag.
Lingua originaleEnglish
pagine (da-a)1437-1440
Numero di pagine4
RivistaRheumatology International
Volume30
Stato di pubblicazionePublished - 2010

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2745???
  • ???subjectarea.asjc.2700.2723???
  • ???subjectarea.asjc.2400.2403???

Fingerprint

Entra nei temi di ricerca di 'A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis'. Insieme formano una fingerprint unica.

Cita questo